Atossa Genetics Stock Performance
| ATOS Stock | USD 0.66 0.03 4.35% |
The firm shows a Beta (market volatility) of 0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Atossa Genetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Atossa Genetics is expected to be smaller as well. At this point, Atossa Genetics has a negative expected return of -0.34%. Please make sure to confirm Atossa Genetics' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Atossa Genetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Atossa Genetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 88.6 M | |
| Total Cashflows From Investing Activities | -19 K | |
| Free Cash Flow | -21 M |
Atossa Genetics Relative Risk vs. Return Landscape
If you would invest 87.00 in Atossa Genetics on September 29, 2025 and sell it today you would lose (21.00) from holding Atossa Genetics or give up 24.14% of portfolio value over 90 days. Atossa Genetics is currently does not generate positive expected returns and assumes 4.2148% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Atossa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Atossa Genetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atossa Genetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Atossa Genetics, and traders can use it to determine the average amount a Atossa Genetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0812
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATOS |
Based on monthly moving average Atossa Genetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Atossa Genetics by adding Atossa Genetics to a well-diversified portfolio.
Atossa Genetics Fundamentals Growth
Atossa Stock prices reflect investors' perceptions of the future prospects and financial health of Atossa Genetics, and Atossa Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Atossa Stock performance.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 36.81 M | ||||
| Shares Outstanding | 129.17 M | ||||
| Price To Earning | (0.62) X | ||||
| Price To Book | 1.78 X | ||||
| EBITDA | (27.6 M) | ||||
| Cash And Equivalents | 125.54 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 4.97 M | ||||
| Book Value Per Share | 0.39 X | ||||
| Cash Flow From Operations | (21.03 M) | ||||
| Earnings Per Share | (0.23) X | ||||
| Total Asset | 76.44 M | ||||
| Retained Earnings | (211.79 M) | ||||
| Current Asset | 4.29 M | ||||
| Current Liabilities | 2.5 M | ||||
About Atossa Genetics Performance
Assessing Atossa Genetics' fundamental ratios provides investors with valuable insights into Atossa Genetics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Atossa Genetics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.Things to note about Atossa Genetics performance evaluation
Checking the ongoing alerts about Atossa Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Atossa Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Atossa Genetics generated a negative expected return over the last 90 days | |
| Atossa Genetics has some characteristics of a very speculative penny stock | |
| Atossa Genetics has high historical volatility and very poor performance | |
| Net Loss for the year was (25.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Atossa Genetics currently holds about 125.54 M in cash with (21.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Atossa Genetics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: How Whitehawk Therapeutics Inc. stock trades after earnings - 2025 Risk Factors Safe Capital Growth Trade Ideas - Newser |
- Analyzing Atossa Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Atossa Genetics' stock is overvalued or undervalued compared to its peers.
- Examining Atossa Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Atossa Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Atossa Genetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Atossa Genetics' stock. These opinions can provide insight into Atossa Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.